Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.51 |
| ▸ | MAOA | P21397 | 14/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825668 | 0.78 | MAOB (0.61) | MAOBMAOA | |
| SCHEMBL6172429 | 0.76 | HRH3 (0.55) | MAOBMAOAHRH3 | |
| SCHEMBL6176700 | 0.76 | MIF (0.51) | — | |
| SCHEMBL6176697 | 0.76 | MIF (0.51) | — | |
| SCHEMBL2354549 | 0.72 | CYP17A1 (0.51) | MAOBMAOA | |
| SCHEMBL14287612 | 0.72 | MAOB (0.54) | MAOBMAOA | |
| SCHEMBL6825249 | 0.71 | MAOB (0.66) | MAOBMAOAHRH3 | |
| SCHEMBL6841878 | 0.69 | MAOA (0.47) | MAOBMAOA | |
| SCHEMBL6172091 | 0.69 | MAOA (0.47) | MAOBMAOA | |
| SCHEMBL9222772 | 0.69 | MAOB (0.69) | MAOBMAOAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966446-B1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER LAMBERT CO (US) | 2005-10-19 | — | — | EP | claimed |
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | BIKKER JACK (US) | 2002-01-17 | — | — | US | claimed |
| US-6265422-B1 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | claimed |
| EP-0966446-B1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER LAMBERT CO (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6528535-B2 | Anticancer agents; restenosis | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | BIKKER JACK (US) | 2002-01-17 | — | — | US | disclosed |
| US-6265422-B1 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6133303-A | VARIOUS INDENE DERIVATIVES, WITH THE EXCEPTION OF 5-(2-IMIDAZOLE-1-YL-ETHOXY)INDAN-1-ONE; TREATING CANCER AND TREATING OR PREVENTING RESTENOSIS OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0966446-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998034921-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | FNTA, FNTB, SREBF1 | MAOB 3449/4885MAOA 3541/4885HRH3 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.